Explore

CGTCA23

Cell & Gene Therapy Research & Development Congress Asia 2023

Taipei, Taiwan, Republic Of China
7 - 8 March 2023
The conference ended on 08 March 2023

Important Dates

Abstract Submission Deadline
20th January 2023
Abstract Acceptance Notification
20th January 2023
Final Abstract / Full Paper Deadline
3rd February 2023
Early Bird Deadline
3rd February 2023

About CGTCA23

This new conference for 2023 focuses on the advances being made in cell and gene therapies which have rapidly become an integral and vital component of modern medicine.

Topics

Gene therapy, Stem cell, Cell therapy, Immunotherapy, Genetic engineering and r-dna technology

Call for Papers

Cell & Gene Therapy Research & Development Congress Asia

Although regenerative therapies are relatively new, more & more hospitals are incorporating cell and gene treatments to treat patients, driving up investment in this sector. World-wide 30 cell and gene therapies have been authorised for large scale production. Looking to the future, biopharmaceutical and biotech companies, and other stakeholders, including regulators and researchers will need to collaborate to develop a new pipeline of research from biological concept to medical practice.

This new conference for 2020 focuses on the advances being made in cell and gene therapies which have rapidly become an integral and vital component of modern medicine.  With more than 30 presentations across two days, the Cell & Gene Therapy Research & Development Congress Asia will provide a platform for leading biopharma and biotech leaders, academicians and researchers to discuss topics on emerging advances in the field of cell and gene therapy, the regenerative potential of stem cells, application of T- cells and Cart-T in the field of immuno-oncology, novel gene-editing tools and delivery methods, vector development, regulatory approaches, ethical considerations and more.

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.